Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Chennai, Nov. 26 -- Highlights: ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...

The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible – ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

CRISPR technology, a revolutionary tool in genetic engineering, has empowered Lambert's iGEM team to tackle a significant health issue: Lyme disease, which affects nearly half a million Americans ...

Although existing CRISPR-Cas-based imaging methods can target endogenous genomic sequences, their applications are limited by system complexity and sensitivity, particularly when imaging ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

Higher yields, greater resilience to climatic changes or diseases—the demands on crop plants are constantly growing. To ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...